Raxibacumab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism.
Journal: Expert opinion on drug safety
Published: August 18, 2023
Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 17, 2022
Survival of Patient With Hemorrhagic Meningitis Associated With Inhalation Anthrax.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 06, 2022
Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives.
Journal: ACS infectious diseases
Published: January 31, 2022
A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis.
Journal: Frontiers in microbiology
Published: October 27, 2021
Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?
Journal: Frontiers in medicine
Published: July 22, 2021
Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years.
Journal: British journal of clinical pharmacology
Published: December 11, 2020
Population pharmacokinetics of raxibacumab in healthy adult subjects.
Journal: British journal of clinical pharmacology
Published: December 11, 2020
Raxibacumab: a panacea for anthrax disease?
Journal: The Lancet. Infectious diseases
Published: February 28, 2020
Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.
Journal: The Lancet. Infectious diseases
Published: November 15, 2019
Monoclonal Antibodies Against Infectious Microbes: So Long and Too Little!
Journal: Infectious disorders drug targets
Published: August 21, 2019
Last Updated: 06/30/2026